JAK2 and essential thrombocythemia: A mutation in the JAK2 kinase domain is found in approximately 95% of patients with polycythemia vera (PV) and 50% of patients with essential thrombocytosis (ET) and myelofibrosis (MF), which causes pathogenesis at the molecular level (James et al., 2005; Kralovics et al., 2005).